Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis

To evaluate whether patients with multiple myeloma (MM) could benefit from tandem autologous hematopoietic stem cell transplantation (auto-HSCT), PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched, and 10 eligible studies were included after data extraction an...

Full description

Saved in:
Bibliographic Details
Main Authors: Hongtao Li, Yaxin Zheng, Kehai Gao, Chen Tian
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Hematology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2024.2343164
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850123815898578944
author Hongtao Li
Yaxin Zheng
Kehai Gao
Chen Tian
author_facet Hongtao Li
Yaxin Zheng
Kehai Gao
Chen Tian
author_sort Hongtao Li
collection DOAJ
description To evaluate whether patients with multiple myeloma (MM) could benefit from tandem autologous hematopoietic stem cell transplantation (auto-HSCT), PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched, and 10 eligible studies were included after data extraction and quality evaluation. Meta-analysis showed that compared to single autologous hematopoietic stem cell transplantation, tandem auto-HSCT does not improve OS, EFS or efficacy in MM patients, and may even lead to higher treatment-related mortality (TRM). MM patients who received autologous tandem allogeneic HSCT did not achieve better response compared to tandem autologous HSCT. In summary, compared to single autologous hematopoietic stem cell transplantation, tandem autologous hematopoietic stem cell transplantation cannot provide survival advantages for MM patients, and MM patients cannot benefit from autologous tandem allogeneic hematopoietic stem cell transplantation.
format Article
id doaj-art-0dd7212b08d94dd09eded9a84e1a4a3d
institution OA Journals
issn 1607-8454
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series Hematology
spelling doaj-art-0dd7212b08d94dd09eded9a84e1a4a3d2025-08-20T02:34:31ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2343164Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysisHongtao Li0Yaxin Zheng1Kehai Gao2Chen Tian3Department of Spinal Orthopedics, Weifang Yidu Central Hospital, Shandong, People’s Republic of ChinaDepartment of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaDepartment of Spinal Orthopedics, Weifang Yidu Central Hospital, Shandong, People’s Republic of ChinaDepartment of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, People’s Republic of ChinaTo evaluate whether patients with multiple myeloma (MM) could benefit from tandem autologous hematopoietic stem cell transplantation (auto-HSCT), PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched, and 10 eligible studies were included after data extraction and quality evaluation. Meta-analysis showed that compared to single autologous hematopoietic stem cell transplantation, tandem auto-HSCT does not improve OS, EFS or efficacy in MM patients, and may even lead to higher treatment-related mortality (TRM). MM patients who received autologous tandem allogeneic HSCT did not achieve better response compared to tandem autologous HSCT. In summary, compared to single autologous hematopoietic stem cell transplantation, tandem autologous hematopoietic stem cell transplantation cannot provide survival advantages for MM patients, and MM patients cannot benefit from autologous tandem allogeneic hematopoietic stem cell transplantation.https://www.tandfonline.com/doi/10.1080/16078454.2024.2343164Tandem autologous transplantationmultiple myelomaprognosismeta-analysis
spellingShingle Hongtao Li
Yaxin Zheng
Kehai Gao
Chen Tian
Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis
Hematology
Tandem autologous transplantation
multiple myeloma
prognosis
meta-analysis
title Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis
title_full Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis
title_fullStr Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis
title_full_unstemmed Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis
title_short Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis
title_sort tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma a systematic review and meta analysis
topic Tandem autologous transplantation
multiple myeloma
prognosis
meta-analysis
url https://www.tandfonline.com/doi/10.1080/16078454.2024.2343164
work_keys_str_mv AT hongtaoli tandemautologoushematopoieticstemcelltransplantationforpatientswithmultiplemyelomaasystematicreviewandmetaanalysis
AT yaxinzheng tandemautologoushematopoieticstemcelltransplantationforpatientswithmultiplemyelomaasystematicreviewandmetaanalysis
AT kehaigao tandemautologoushematopoieticstemcelltransplantationforpatientswithmultiplemyelomaasystematicreviewandmetaanalysis
AT chentian tandemautologoushematopoieticstemcelltransplantationforpatientswithmultiplemyelomaasystematicreviewandmetaanalysis